Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

JAHA editors retract study linking e-cigarette use to MIs

The editors of the Journal of the American Heart Association have retracted a study that linked some-day and everyday e-cigarette use to an increased risk of having had a heart attack. The same study alleged the effect of e-cigarettes was comparable to those of conventional cigarettes.

Thumbnail

New LDL-C guidelines make optimal treatment unaffordable for many in Europe

A study published in the European Heart Journal on Feb. 18 suggests healthcare expenditures in Europe would skyrocket if local systems adopted experts’ latest guidelines for cholesterol-lowering treatment.

Thumbnail

Heart disease more common in women who have suffered domestic abuse

Women who have suffered domestic abuse are 31% more likely to develop heart disease and 51% more likely to develop type 2 diabetes than women who haven’t been abused, a study out of the U.K. has found.

Thumbnail

Diabetics turning to discount insulin from unregulated online marketplaces

Many Americans who can’t afford prescription insulin for their diabetes are turning to unregulated, illegal markets for discounted products, researchers reported in JAMA Internal Medicine this month.

Thumbnail

1 in 5 kids estimated to have high blood pressure

Some 20% of children have high blood pressure, WBAL-TV reported Feb. 17.

Children hit hard as flu refuses to concede ground to Covid-19

As the world waits and watches to see what the coronavirus does next, the bad old flu is getting a second wind in the U.S.—and children may be bearing the brunt.

Thumbnail

Optimism reduces stroke severity

Stroke survivors who are optimistic about their recovery demonstrate lower levels of inflammation and physical disability than their less-cheerful counterparts, researchers reported at the Nursing Symposium of the American Stroke Association’s International Stroke Conference.

Thumbnail

America’s most expensive CV drug needs a 93% price cut

A 92.6% reduction in the list price of tafamidis—an effective but ultimately unaffordable drug designed to treat transthyretin amyloid cardiomyopathy—would be required to make the medication accessible to the average heart patient, researchers reported in Circulation Feb. 12.